BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parmar DR, Soni JY, Guduru R, Rayani RH, Kusurkar RV, Vala AG, Talukdar SN, Eissa IH, Metwaly AM, Khalil A, Zunjar V, Battula S. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg Chem 2021;115:105206. [PMID: 34339975 DOI: 10.1016/j.bioorg.2021.105206] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 32.0] [Reference Citation Analysis]
Number Citing Articles
1 Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB, Alsfouk AA, Alesawy MS, Metwaly AM, Eissa IH. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzyme Inhib Med Chem 2022;37:1903-17. [PMID: 35801403 DOI: 10.1080/14756366.2022.2085693] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
2 Elkaeed EB, Taghour MS, Mahdy HA, Eldehna WM, El-Deeb NM, Kenawy AM, A Alsfouk B, Dahab MA, Metwaly AM, Eissa IH, El-Zahabi MA. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J Enzyme Inhib Med Chem 2022;37:2191-205. [PMID: 35975321 DOI: 10.1080/14756366.2022.2110869] [Reference Citation Analysis]
3 Gaber AA, Sobhy M, Turky A, Abdulwahab HG, Al-Karmalawy AA, Elhendawy MA, Radwan MM, Elkaeed EB, Ibrahim IM, Elzahabi HSA, Eissa IH. Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M. J Enzyme Inhib Med Chem 2022;37:2283-303. [PMID: 36000168 DOI: 10.1080/14756366.2022.2112575] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Elkaeed EB, Khalifa MM, Alsfouk BA, Alsfouk AA, El-attar AMM, Eissa IH, Metwaly AM. The Discovery of Potential SARS-CoV-2 Natural Inhibitors among 4924 African Metabolites Targeting the Papain-like Protease: A Multi-Phase In Silico Approach. Metabolites 2022;12:1122. [DOI: 10.3390/metabo12111122] [Reference Citation Analysis]
5 Zahran SS, Ragab FA, El-gazzar MG, Soliman AM, Mahmoud WR, Ghorab MM. Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114912] [Reference Citation Analysis]
6 Elkaeed EB, Yousef RG, Elkady H, Mehany ABM, Alsfouk BA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative. J Biomol Struct Dyn 2022;:1-16. [PMID: 36184591 DOI: 10.1080/07391102.2022.2127907] [Reference Citation Analysis]
7 Elkaeed EB, Yousef RG, Khalifa MM, Ibrahim A, Mehany ABM, Gobaara IMM, Alsfouk BA, Eldehna WM, Metwaly AM, Eissa IH, El-zahabi MA. Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies. Molecules 2022;27:6203. [DOI: 10.3390/molecules27196203] [Reference Citation Analysis]
8 Kusurkar RV, Rayani RH, Parmar DR, Patel DR, Patel MJ, Pandey NO, Zunjar V, Soni JY. Phenyl Substituted 3-Chloro 2-azetidinones: Design, Green Synthesis, Antimicrobial Activity, and Molecular Docking Studies. Journal of Molecular Structure 2022. [DOI: 10.1016/j.molstruc.2022.134185] [Reference Citation Analysis]
9 Metwaly AM, Elwan A, El-attar AMM, Al-rashood ST, Eissa IH, Singh AK. Structure-Based Virtual Screening, Docking, ADMET, Molecular Dynamics, and MM-PBSA Calculations for the Discovery of Potential Natural SARS-CoV-2 Helicase Inhibitors from the Traditional Chinese Medicine. Journal of Chemistry 2022;2022:1-23. [DOI: 10.1155/2022/7270094] [Reference Citation Analysis]
10 Suleimen YM, Jose RA, Mamytbekova GK, Suleimen RN, Ishmuratova MY, Dehaen W, Alsfouk BA, Elkaeed EB, Eissa IH, Metwaly AM. Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-O-(6″-O-acetyl)-Glucoside from Calligonum tetrapterum. Plants 2022;11:2072. [DOI: 10.3390/plants11152072] [Reference Citation Analysis]
11 Wu J, Kong L, Yi M, Chen Q, Cheng Z, Zuo H, Yang Y, Wei L. Prediction and Screening Model for Products Based on Fusion Regression and XGBoost Classification. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/4987639] [Reference Citation Analysis]
12 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk BA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules 2022;27:4606. [DOI: 10.3390/molecules27144606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk AA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes 2022;10:1391. [DOI: 10.3390/pr10071391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
14 Azab AE, Alesawy MS, Eldehna WM, Elwan A, Eissa IH. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. Arch Pharm (Weinheim) 2022;:e2200133. [PMID: 35822666 DOI: 10.1002/ardp.202200133] [Reference Citation Analysis]
15 Yousef RG, Eldehna WM, Elwan A, Abdelaziz AS, Mehany ABM, Gobaara IMM, Alsfouk BA, Elkaeed EB, Metwaly AM, Eissa IH. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules 2022;27:4079. [DOI: 10.3390/molecules27134079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-seri SM, Metwaly AM. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. IJMS 2022;23:6912. [DOI: 10.3390/ijms23136912] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
17 Yousef RG, Ibrahim A, Khalifa MM, Eldehna WM, Gobaara IMM, Mehany ABM, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J Enzyme Inhib Med Chem 2022;37:1389-403. [PMID: 35577416 DOI: 10.1080/14756366.2022.2070744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
18 El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Abulkhair HS, Eissa IH. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Arch Pharm (Weinheim) 2022;:e2200048. [PMID: 35437829 DOI: 10.1002/ardp.202200048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Suleimen YM, Jose RA, Suleimen RN, Ishmuratova MY, Toppet S, Dehaen W, Alsfouk AA, Elkaeed EB, Eissa IH, Metwaly AM. Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca. Molecules 2022;27:2281. [PMID: 35408682 DOI: 10.3390/molecules27072281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
20 Eissa IH, Alesawy MS, Saleh AM, Elkaeed EB, Alsfouk BA, El-attar AMM, Metwaly AM. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules 2022;27:2287. [DOI: 10.3390/molecules27072287] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
21 Elkaeed EB, Elkady H, Belal A, Alsfouk BA, Ibrahim TH, Abdelmoaty M, Arafa RK, Metwaly AM, Eissa IH. Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes 2022;10:530. [DOI: 10.3390/pr10030530] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
22 Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova MY, Toppet S, Dehaen W, Alsfouk BA, Elkaeed EB, Eissa IH, Metwaly AM. Jusanin, a New Flavonoid from Artemisia commutata with an In Silico Inhibitory Potential against the SARS-CoV-2 Main Protease. Molecules 2022;27:1636. [PMID: 35268738 DOI: 10.3390/molecules27051636] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
23 Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova M, Toppet S, Dehaen W, Alsfouk AA, Elkaeed EB, Eissa IH, Metwaly AM. Isolation and In Silico Anti-SARS-CoV-2 Papain-like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from Artemisia spp. Molecules 2022;27:1216. [DOI: 10.3390/molecules27041216] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
24 Alharbi W. Advancement and recent trends in seeking less toxic and more active anti-cancer drugs: Insights into thiourea based molecules. MGC 2022. [DOI: 10.3233/mgc-210183] [Reference Citation Analysis]
25 Mohammed SO, El Ashry SHE, Khalid A, Amer MR, Metwaly AM, Eissa IH, Elkaeed EB, Elshobaky A, Hafez EE. Expression, Purification, and Comparative Inhibition of Helicobacter pylori Urease by Regio-Selectively Alkylated Benzimidazole 2-Thione Derivatives. Molecules 2022;27:865. [PMID: 35164122 DOI: 10.3390/molecules27030865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
26 Berk Ş, Kaya S, Akkol EK, Bardakçı H. A comprehensive and current review on the role of flavonoids in lung cancer-Experimental and theoretical approaches. Phytomedicine 2022;98:153938. [PMID: 35123170 DOI: 10.1016/j.phymed.2022.153938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Rayani RH, Soni JY, Parmar DR, Kusurkar RV, Eissae I, Metwaly AM, Khalil A, Zunjar V, Battula S, Niazi S. Identification of new pyrazolyl piperidine molecules as factor Xa inhibitors: Design, synthesis, in silico, and biological evaluation. Results in Chemistry 2022;4:100355. [DOI: 10.1016/j.rechem.2022.100355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hagras M, Saleh MA, Ezz Eldin RR, Abuelkhir AA, Khidr EG, El-Husseiny AA, El-Mahdy HA, Elkaeed EB, Eissa IH. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J Enzyme Inhib Med Chem 2022;37:380-96. [PMID: 34923885 DOI: 10.1080/14756366.2021.2015342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 Babalola BA, Adetobi TE, Akinsuyi OS, Adebisi OA, Folajimi EO. Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2. COVID 2021;1:757-74. [DOI: 10.3390/covid1040061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem 2022;37:299-314. [PMID: 34894955 DOI: 10.1080/14756366.2021.2007905] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
31 Alesawy MS, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies. Molecules 2021;26:6593. [PMID: 34771004 DOI: 10.3390/molecules26216593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
32 Eissa IH, Khalifa MM, Elkaeed EB, Hafez EE, Alsfouk AA, Metwaly AM. In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10. Molecules 2021;26:6151. [PMID: 34684735 DOI: 10.3390/molecules26206151] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
33 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA, Mahdy HA. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg Med Chem 2021;46:116384. [PMID: 34479065 DOI: 10.1016/j.bmc.2021.116384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]